NCT00749320 - Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Renal Cell Carcinoma

Interventions

OTHER

Arterial Spin Labeling Magnetic Resonance Imaging

ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC

Trial Locations (2)

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston